SCHEMBL19988532

SCHEMBL19988532

c1ccc2nc3c(nc2c1)c1c2ccccc2[nH]c1c1oc2ccccc2c31

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K11 Q16584 2/20 0.51
▸ MAP3K9 P80192 1/20 0.51
▸ POLB P06746 4/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ MAPK10 P53779 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ CASP1 P29466 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ CASP7 P55210 1/20 0.45
▸ PIM1 P11309 1/20 0.44
▸ PIM3 Q86V86 1/20 0.44
▸ PIM2 Q9P1W9 1/20 0.44
▸ DYRK1A Q13627 3/20 0.42
▸ KMT2A Q03164 3/20 0.40
▸ HPGD P15428 3/20 0.40
▸ HSD17B10 Q99714 3/20 0.40
▸ USP2 O75604 2/20 0.40
▸ CREBBP Q92793 2/20 0.40
▸ TSHR P16473 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19988529 0.81 MAP3K11 (0.49) MAP3K11MAP3K9SMN1; SMN2DYRK1AKMT2A
SCHEMBL29506369 0.81 MAP3K11 (0.59) MAP3K11MAP3K9POLBRAB9ADYRK1A
SCHEMBL30883881 0.81 MAP3K11 (0.59) MAP3K11MAP3K9POLBRAB9ADYRK1A
SCHEMBL17228831 0.81 MAP3K11 (0.59) MAP3K11MAP3K9POLBRAB9ADYRK1A
SCHEMBL19974124 0.80 MAP3K11 (0.53) MAP3K11MAP3K9DYRK1AGABRPGABRD
SCHEMBL19988566 0.80 MAP3K11 (0.53) MAP3K11MAP3K9DYRK1AKDM4EGABRP
SCHEMBL19991873 0.78 MAP3K11 (0.56) MAP3K11MAP3K9POLBRAB9ADYRK1A
SCHEMBL19988562 0.77 MAP3K11 (0.46) MAP3K11MAP3K9POLBSMN1; SMN2NPC1
SCHEMBL19988559 0.76 MAP3K11 (0.47) MAP3K11MAP3K9SMN1; SMN2DYRK1AKDM4E
SCHEMBL19988560 0.76 MAP3K11 (0.47) MAP3K11MAP3K9SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512848-B1 COMPOUNDS WITH CARBAZOLE STRUCTURES MERCK PATENT GMBH (DE) 2020-11-18 — — EP disclosed
US-20190214574-A1 COMPOUNDS WITH CARBAZOLE STRUCTURES MERCK PATENT GMBH (DE) 2019-07-11 — — US disclosed
WO-2018050583-A1 COMPOUNDS WITH CARBAZOLE STRUCTURES MERCK PATENT GMBH (DE) 2018-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190214574-A1 COMPOUNDS WITH CARBAZOLE STRUCTURES CYCS, CYP3A4, CYP2E1 MAP3K11 1974/4885MAP3K9 1892/4885POLB 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback